Taro Receives Patent for New Drug

Taro Pharmaceutical Industries Ltd. have announced that the U.S. Patent and Trademark Office has issued the company a patent for its non-sedating barbiturate drug T2007, which is currently under development.

T2007 is the sodium salt of DPB (diphenyl barbituric acid), and its use is directed to its anti-epileptic properties. In animal models, DPB has an efficacy comparable to phenobarbital, a long-established clinical treatment for epilepsy.

We view this development with interest. Taro is yet another Israel based pharmaceutical company that appears to be moving into the ethical drug development area.  That said, Sun Pharmaceuticals are trying to buy up Taro, so it might end up an Indian company.

Categories: drugs, India, Intellectual Property, News, Patents, pharmaceuticals, pharmaceuticals and Biotechnology

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: